1 / 9

Pet Cancer Therapeutics Market forecast to see growth of 10% CAGR from 2017 to 2024

Get more details @ http://bit.ly/2vzOqU5 <br>The Pet cancer therapeutics sector is a relatively new compared to other pet healthcare sectors. Increasing trend of pet adoption such as dogs and cats owing to improved economic status of people will drive pet cancer therapeutics market size.

jueekate
Download Presentation

Pet Cancer Therapeutics Market forecast to see growth of 10% CAGR from 2017 to 2024

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Pet Cancer Therapeutics Market share to hit $300mn by 2024: Global Market Insights Inc. Fuel Cell Market size worth $25.5bn by 2024

  2. Key Insights from Pet Cancer Therapeutics Market: • Launching of Tanovea-CA1, the FDA approved animal drug for treating canine lymphoma is indeed a breakthrough in pet cancer therapeutics market. • Synonymous with lymphosarcoma, this detrimental disease is the most common type of cancer affecting dogs. • Center for Veterinary Medicine, a subsidiary of U.S Food and Administration has recently announced a partial approval to this groundbreaking anti-cancer drug and depending upon the effectiveness, market experts anticipates its full approval within few years. • A Colorado State University startup, VetDC Inc., is commercially merchandizing these drugs and are presently available in the U.S. market by licensed veterinarians. Reportedly, TANOVEA-CA1 is the only effective animal drug available in pet cancer therapeutics market for the treatment of lymphoma. • In veterinary oncology, chemotherapy is the most recognized therapeutic model that is extensively deployed as one of the most relatively effective methodologies of treatment. In fact, in 2016, chemotherapy held the largest share of the overall pet cancer therapeutics industry.

  3. Continued... • In case of pet cancer treatment, outgrowth of cancer cells is tried to limit as much as possible but not at the cost of their quality of life. • However, it has been noticed that cats and dogs respond to chemotherapy much better than humans, which again is pushing pet cancer therapeutics market from chemotherapy. • Blue Buffalo Foundation and The Petco Foundation have entered a partnership to provide a grant of USD 750000 to Morris Animal Foundation. • Reportedly this grand sum of investment is an initiative taken to fund Morris Animal Foundation’s research initiative related to osteosarcoma and other additional studies related to pet cancer. • As per a recent report put forward by Global Market Insights, Inc., Pet cancer therapeutics market is forecast to exceed a revenue of USD 300 million by 2024, with a projected CAGR of 10% over 2017-2024. • Some of the prominent biggies in the pet cancer therapeutics market include Zoetis, Aratana Therapeutics Merial, AB Science, VetDC, Vetivax, KaryopharmsVerdinexor, and Regeneus.

  4. U.S Pet cancer therapeutics market, by medicine type, 2013 - 2024 (USD Million)

  5. Table of Content: • Chapter 1. Methodology • 1.1. Methodology • 1.1.1. Initial data exploration • 1.1.2. Statistical model and forecast • 1.1.3. Industry insights and validation • 1.1.4. Market definition & forecast parameters • 1.2. Data sources • 1.2.1. Secondary • 1.2.2. Primary • Chapter 2. Executive Summary • 2.1. Pet cancer therapeutics market 3600 synopsis, 2013 –2024 • 2.1.1. Business trends • 2.1.2. Medicine type trends • 2.1.3. Species trends • 2.1.4. Cancer type trends • 2.1.5. Regional trends

  6. Table of Content: • Chapter 3. Pet cancer therapeutics Industry Insights • 3.1. Industry segmentation • 3.2. Industry size and forecast, 2013 - 2024 • 3.3. Industry impact forces • 3.3.1. Growth drivers • 3.3.1.1. Rising number of pets’ population • 3.3.1.2. Increasing prevalence of cancer in pets • 3.3.1.3. Rising willingness of pet owners to spend on pet healthcare • 3.3.1.4. Increasing number of new product development • 3.3.2. Industry pitfalls & challenges • 3.3.2.1. Side-effects of Pet cancer therapeutics • 3.3.2.2. Dearth of veterinary oncologist • 3.3.2.3. Low out of pocket expenditure on pet healthcare in developing countries

  7. Table of Content: • 3.4. Regulatory landscape • 3.4.1. U.S. • 3.4.2. Europe • 3.5. Technology landscape • 3.5.1. North America • 3.5.2. Europe • 3.6. Pipeline analysis • 3.7. Growth potential analysis • 3.8. Porter's analysis • 3.9. Competitive landscape, 2016 • 3.10. PESTEL analysis

  8. Browse Full Market Research Report On Pet Cancer Therapeutics Market @ http://bit.ly/2fxZquX Request for a Sample of this Research Report @ https://www.gminsights.com/request-sample/detail/2017https://www.gminsights.com/request-sample/detail/49

  9. Stay In Touch Website: www.gminsights.com Social Media:

More Related